Solventum Co. (NYSE:SOLV) Shares Acquired by First Trust Advisors LP

First Trust Advisors LP boosted its holdings in shares of Solventum Co. (NYSE:SOLV - Free Report) by 147.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 139,990 shares of the company's stock after acquiring an additional 83,458 shares during the period. First Trust Advisors LP owned 0.08% of Solventum worth $9,248,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Modus Advisors LLC acquired a new stake in shares of Solventum in the 4th quarter worth $25,000. Stonebridge Financial Group LLC acquired a new stake in shares of Solventum during the 4th quarter worth approximately $26,000. Crews Bank & Trust purchased a new stake in shares of Solventum during the 4th quarter valued at approximately $32,000. Synergy Asset Management LLC acquired a new position in Solventum in the fourth quarter valued at approximately $35,000. Finally, Spire Wealth Management acquired a new stake in Solventum during the fourth quarter worth $37,000.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on SOLV shares. The Goldman Sachs Group lifted their price target on shares of Solventum from $63.00 to $71.00 and gave the company a "sell" rating in a research report on Monday, March 3rd. Wells Fargo & Company upped their price target on Solventum from $73.00 to $75.00 and gave the stock an "equal weight" rating in a research note on Friday, February 28th. Morgan Stanley lifted their price objective on Solventum from $73.00 to $80.00 and gave the company an "equal weight" rating in a research note on Wednesday, March 5th. Piper Sandler lowered their target price on Solventum from $84.00 to $80.00 and set a "neutral" rating for the company in a report on Wednesday. Finally, Mizuho boosted their price target on shares of Solventum from $70.00 to $82.00 and gave the stock a "neutral" rating in a research note on Monday, March 3rd. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and one has given a buy rating to the company's stock. Based on data from MarketBeat, Solventum currently has a consensus rating of "Hold" and a consensus price target of $79.29.

Solventum Stock Up 3.2 %

Shares of SOLV stock traded up $2.07 during trading hours on Friday, reaching $67.69. 990,233 shares of the stock were exchanged, compared to its average volume of 1,286,094. The business's fifty day moving average is $71.91 and its two-hundred day moving average is $71.49. The firm has a market capitalization of $11.71 billion and a P/E ratio of 24.61. Solventum Co. has a 12-month low of $47.16 and a 12-month high of $85.92. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.